Quay Pharmaceuticals is experienced in providing a comprehensive out-sourcing service for formulation and analytical development with subsequent clinical trials manufacturing for pharmaceutical and biotechnology companies world-wide. Working as a dedicated, pro-active part of your team we apply strong project management and technical expertise to take products quickly and cost effectively from late stage pre-clinical through to the end of phase III clinical trials and commercial manufacturing. Quay Pharma has vast expertise in dosage form design and development and with Professor Mike Rubinstein (CEO), Prof L Gifford (CSO) and Professor John Collett (CSO), Quay Pharma has built a reputation for specialising in the formulation of API’s that exhibit poor solubility and bio-availability and those which require modified or controlled release. We are now a MHRA and FDA inspected and approved company.
Quay Pharma news articles
25 June 2020
Quay Pharma Knowledge Transfer Partnership (KTP) announcement
30 September 2019
Quay Pharma partnering this years Microbiome Movement – Drug Development & Nutrition Asia Summit
2 November 2016
Quay Pharma to supply promising cancer drug for trial